Clinical trials: Cachexia; Cancer; Sarcopenia
Cancer Cachexia, Sarcopenia
Targeting Muscle-Bone Crosstalk Through Physical Therapy in Cancer Cachexia
This study investigates the role of a structured physical therapy (PT) program in managing cancer-induced cachexia (CIC) by targeting muscle-bone crosstalk.
- Trial name
- PU-PTCC (NCT07807306)
- Testing
- Structured Physical Therapy Exercise Program
- Volunteers
- 40 people
- Sponsor
- Pharos University in Alexandria
Non Small Cell Lung Cancer
Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC
The study aim to evaluate whether some substances produced by muscle or adipose tissue may play a role in the course of the disease by interfering with the effectiveness of therapies.
- Trial name
- SARCLUNG (NCT06808113)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Cirrhosis, Cancer
Influence of Sarcopenia on the Course of the Diseases
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as…
- Conditions
- Liver Cirrhosis, Cancer, Cachexia, Sarcopenia
- Trial name
- NCT06829290
- Testing
- Ultrasound
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Universitatsmedizin Mainz - 1. Medizinische Klinik
Cachexia
Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II
The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future…
- Trial name
- 3MH-2 (NCT01694602)
- Testing
- (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Cachexia, Neoplasms
Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms
Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of >5% within 6 months and it occurs in 50-80%…
- Conditions
- Cachexia, Neoplasms, Exercise, Metabolism
- Trial name
- PANACEA (NCT05307367)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Weight Loss, Cachexia
Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)
Weight loss and loss of lean body mass are common and associated with adverse outcomes such as loss of strength, reduced immune- and pulmonary function and increased disability in advanced cancer.
- Trial name
- LEKS (NCT01865903)
- Where
- Norway
- Volunteers
- 17 people
- Sponsor
- Oslo University Hospital
Cancer, Hospitalizations
Multidomain Bedside Assessment of Short-Term Mortality and Readmission in Hospitalized Patients With Metastatic Cancer
This prospective observational study evaluated whether simple bedside assessments performed during an unplanned hospitalization were associated with short-term outcomes in adults with metastatic solid cancer.
- Conditions
- Cancer, Hospitalizations, Sarcopenia, Cachexia; Cancer; Sarcopenia
- Trial name
- PRO-HAND (NCT07167082)
- Testing
- Handgrip Strength Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 233 people
- Sponsor
- Ankara Etlik City Hospital
Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
Sarcopenia and Cachexia in Patients With Lung Cancer
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer.
- Trial name
- PHILUCA (NCT06730685)
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Zealand University Hospital
Gastric Cancer, Sarcopenia
Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer
We aimed to establish the effects of sarcopenia on postoperative complications among patients undergoing surgical treatment for gastric cancer
- Conditions
- Gastric Cancer, Sarcopenia, Malnutrition; Cachexia, Complication
- Trial name
- NCT03958032
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 185 people
- Sponsor
- Karadeniz Technical University
Pancreatic Ductal Adenocarcinoma
Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
The aim of this study is to assess whether prehabilitation supervised by an appropriate multimodality team improves indices of sarcopenia in patients scheduled to undergo pancreatoduodenectomy.
- Trial name
- SIPUP (NCT03770117)
- Testing
- Prehabilitation, Standard Procedure
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Manchester University NHS Foundation Trust
Gastro-esophageal Cancer
Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer
Patients with advanced gastroesophageal cancer are in great risk of losing skeletal muscle mass and developing cancer cachexia. Low skeletal muscle mass has a negative impact on quality of life, impairs physical function…
- Trial name
- NCT05650827
- Testing
- Resistance training, Protein supplement
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cachexia
The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia
Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.
- Trial name
- OFCS (NCT05623852)
- Testing
- fucoidan
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
PDAC, Pancreas Adenocarcinoma (MSI-H)
Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with cancer cachexia, a condition characterized by progressive loss of skeletal muscle mass and strength driven by systemic inflammation.
- Trial name
- NUTRI-MYO (NCT07883161)
- Testing
- HMB / L-Arginine / L-Glutamine oral nutritional mixture, Standard Dietary Counseling
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oncologic Diseases
Muscle Deterioration in Hospitalized Cancer Patient
Cancer cachexia and skeletal muscle deterioration represent significant challenges in oncology, affecting up to 42% of cancer patients and correlating with poor clinical outcomes, increased treatment toxicity, and reduced overall…
- Trial name
- MUSONC (NCT07387770)
- Testing
- Screenig Phase
- Volunteers
- 40 people
- Sponsor
- University of Salamanca
Malnutrition; Cachexia
Influence of Protein Intake on Muscle Mass and Health-related Quality of Life During and After Radiotherapy
The influence of radiotherapy on the protein intake and muscle mass of patients has not been extensively investigated to date. It is also unclear whether the localization of the tumor disease and thus the radiation field have…
- Trial name
- pROtein (NCT06480266)
- Where
- Germany
- Volunteers
- 175 people
- Sponsor
- Charite University, Berlin, Germany
Cachexia; Cancer; Sarcopenia
The Role of the Muscle-nervous System Interface in Cancer Cachexia
Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which can result in better therapeutic…
- Trial name
- NUMANCAN (NCT03477721)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Roma La Sapienza
Cachexia; Cancer; Sarcopenia
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can…
- Trial name
- PRCC-MO (NCT07519837)
- Testing
- Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients, Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- China Medical University, China
Sarcopenia in Elderly, Cachexia; Cancer; Sarcopenia
Body Composition in Older Adults
The primary aim of the study is to explore body composition in older adults (aged 70 years and over) with cancer, undergoing systemic anticancer treatment.
- Conditions
- Sarcopenia in Elderly, Cachexia; Cancer; Sarcopenia, Body Composition Changes, Older Adults
- Trial name
- BODI (NCT06630754)
- Testing
- No Intervention: Observational Cohort
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Liver Cirrhosis, Hepatocellular Carcinoma
Relevance of Sarcopenia in Advanced Liver Disease
Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Sarcopenia, Portal Hypertension
- Trial name
- ACCESS-ESLD (NCT05502198)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Linkoeping University
Gastro-Esophageal Cancer
Cancer-associated Cachexia in Patients With Incurable Gastroesophageal Cancer
Patients with incurable gastroesophageal cancer are at high risk of cancer cachexia with an estimated prevalence of 60-80%. Cancer cachexia is defined as ongoing loss of skeletal muscle mass with or without loss of fat mass and…
- Trial name
- NCT06137508
- Where
- Denmark
- Volunteers
- 125 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet